Cellular Origin of Glioma: From Triggers to Treatments

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 20 January 2026 | Viewed by 23

Special Issue Editor


E-Mail Website
Guest Editor
Brain Tumour Research Lab, School of Pharmacy and Life Sciences, University of Wolverhampton, Wolverhampton WV1 1LY, UK
Interests: epigenetics; cancer; brain; drug therapy; genomics; genetics; adenovirus; mouse models; suppressor genes; drug targeting; solid tumours

Special Issue Information

Dear Colleagues,

An aggressive primary brain tumour, glioblastoma (GBM), is the most common cancer of the central nervous system in adults. However, an inability to identify its cell of origin has been a fundamental issue hindering further understanding of the nature and pathogenesis of GBM, as well as the development of novel therapeutic targets. Researchers have hypothesized that GBM arises from the accumulation of somatic mutations in neural stem cells (NSCs) and glial precursor cells that confer selective growth advantages, leading to uncontrolled proliferation. Understanding the cellular origin of gliomas and the lineage hierarchy of GBM is crucial for accurate diagnosis, effective treatment, and patient outcomes. 

Dr. Katherine Karakoula
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glioblastoma
  • brain tumour
  • tumour heterogeneity
  • targeted therapy
  • glioma stem cells

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop